Fiche centre
Sentara Norfolk General Hospital
Norfolk — United States
Essais liés9clinical trials
VilleNorfolklocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04774159
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Tricuspid Transcatheter Edge-to-Edge Repair (TEER) | Maladie coronarienne | À vérifier | NCT07586995 | TREAT TR — A Post-Market Assessment of the Safety and Performance of the TriClip™ System | RECRUITING |
| Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System | Maladie coronarienne | Non applicable | NCT07308847 | Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360) | ACTIVE_NOT_RECRUITING |
| FARAPULSE™ Pulsed Field Ablation System | Maladie coronarienne | À vérifier | NCT06431815 | ADVENTPAS — ADVENT Post Approval Study | ACTIVE_NOT_RECRUITING |
| FARAPULSE™ Pulsed Field Ablation System | Maladie coronarienne | Non applicable | NCT06735534 | ReMATCH — Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | ACTIVE_NOT_RECRUITING |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 4 | NCT06909565 | V-INTERVENTION — Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | RECRUITING |
| Colchicine 0.5 MG Oral Tablet | Maladie coronarienne | Phase 3 | NCT04774159 | LEADER-PAD — Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Biospecimen Collection | Cancer | Non applicable | NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | RECRUITING |